Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
- 1 January 1998
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 16 (1) , 229-236
- https://doi.org/10.1200/jco.1998.16.1.229
Abstract
PURPOSEThe analogue 131I-metaiodobenzylguanidine (MIBG), which is specifically targeted to neuroblastoma cells, may provide more effective and less toxic treatment for neuroblastoma than convention...Keywords
This publication has 0 references indexed in Scilit: